Nasdaq

Polyrizon Ltd. Files Divisional Patent Application for Trap & Target Platform Technology Enhancing Intranasal Drug Delivery

Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.
Network World

F5 upgrades target application security, AI

New API discovery and protection capabilities are aimed at helping customers secure distributed applications that span on-premises and cloud locations. F5 is reinforcing application security with a ...
Nasdaq

Fortress Biotech's Cyprium Therapeutics Receives Priority Review for CUTX-101 New Drug Application with Target Action Date of June 30, 2025

Priority Review granted for CUTX-101 could expedite its path to market, potentially becoming the first FDA-approved treatment for Menkes disease. Cyprium is eligible to receive up to $129 million in ...
Seeking Alpha

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy ...